Table 1.
Clinical and biochemical data of examined patients
| Parameter | Non MVI group | MVI group | p value |
|---|---|---|---|
| Mean ± SD* (n = 115) | Mean ± SDa (n = 115) | ||
| Sex: female / male (n) | 21 / 94 | 9 / 106 | 0.019 |
| Age (years) | 50.23 ± 12.28 | 48.34 ± 11.00 | 0.221 |
| Drinking: absent / present (n) | 57 / 58 | 52 / 63 | 0.509 |
| Smoking: absent / present (n) | 73 / 42 | 66 / 49 | 0.345 |
| HBsAg: negative / positive (n) | 27 / 88 | 17 / 98 | 0.094 |
| HCVAb: negative / positive (n) | 109 / 6 | 113 / 2 | 0.280 |
| Family history: absent/present (n) | 99 / 16 | 95 / 20 | 0.468 |
| Tumor number: single/multiple (n) | 86 / 29 | 72 / 43 | 0.047 |
| Tumor size (cm) | 6.08 ± 3.32 | 8.53 ± 3.78 | < 0.001 |
| Liver cirrhosis: absent / present (n) | 9 / 106 | 7 / 108 | 0.796 |
| NEUT (× 109/L) | 3.71 ± 1.50 | 4.52 ± 2.24 | 0.001 |
| LYMPH (× 109/L) | 1.77 ± 0.61 | 1.58 ± 0.59 | 0.012 |
| WBC (× 109/L) | 6.17 ± 1.85 | 6.87 ± 2.50 | 0.017 |
| Platelets (× 109/L) | 172.43 ± 72.73 | 180.14 ± 82.65 | 0.453 |
| Albumin (g/L) | 41.32 ± 4.01 | 39.47 ± 4.62 | 0.002 |
| Globulin (g/L) | 29.83 ± 4.79 | 31.34 ± 6.52 | 0.045 |
| TBIL (μmol/L) | 13.22 ± 4.93 | 15.07 ± 12.61 | 0.146 |
| DBIL (μmol/L) | 4.47 ± 2.32 | 5.48 ± 4.10 | 0.022 |
| ALT (U/L) | 37.38 ± 30.49 | 44.05 ± 33.32 | 0.115 |
| AST (U/L) | 39.33 ± 30.06 | 55.15 ± 35.29 | < 0.001 |
| ALP (U/L) | 81.45 ± 87.65 | 102.22 ± 50.98 | 0.030 |
| GGT (U/L) | 59.17 ± 40.61 | 114.51 ± 64.46 | < 0.001 |
| AFP (ng/ml): median, range | 44.60, 1.18–24,200 | 457.80, 0.61–25,410 | 0.271 |
| GLR level | 38.42 ± 33.52 | 84.83 ± 61.84 | < 0.001 |
aData presented as mean ± SD or proportions
n number of patients; HBsAg hepatitis B surface antigen, HCVAb hepatitis C virus antibody, NEUT neutrophil cell count, LYMPH lymphocyte count, WBC white blood cell, TBIL total bilirubin, DBIL direct bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, AFP alpha-fetoprotein, GLR GGT to lymphocyte ratio